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Immune-mediated encephalitis with daclizumab – the final nail.  
 
With the exponential growth in treatment options for active multiple sclerosis 
(MS) comes the need for diligent post-marketing surveillance for adverse effects. 
This is highlighted in this issue by Devlin et al, who provide the first clinico-
pathological report of immune-mediated encephalitis on daclizumab.   
 
Clinical trials identify many safety concerns, but can only provide limited 
exposure of the drug to a highly selected and controlled cohort. Most MS 
treatments carry a black triangle status from the European Medicines Agency 
(EMA), requiring additional monitoring during the initial period of real-world, 
post-marketing experience. Greater patient exposure occurs in a more diverse 
patient group, with more potential for drug-drug and drug-other condition 
interactions. The MS community is all too familiar with this following the initial 
FDA approval and subsequent temporary suspension of natalizumab as 
progressive multifocal leukoencephalopathy cases were recognised. 
 
Daclizumab was authorised in 2016, following consideration of clinical trial data 
from 2,236 exposed patients. Elevated liver enzymes were common, and there 
was one death due to autoimmune hepatitis, but no cases of encephalitis were 
identified in any studies1. Post-marketing surveillance, however, has critically 
swung the risk-benefit balance in favour of product withdrawal.  
 
Despite risk minimisation approaches, a further case of fatal autoimmune 
hepatitis was reported to the EMA pharmacovigilence committee in June 2017, 
resulting in a licencing restriction to those who have tried two previous disease 
modifying therapies and are unsuitable for any others2. In March 2018, however, 
the EMA recommended the immediate suspension of daclizumab following 12 
reports of meningoencephalitis, 3 of which were fatal.3  
 
The report by Devlin et al of such a case of immune-mediated encephalitis 
provides a fascinating insight into the complexity of immune modification in MS. 
It should also serve as a reminder to all of those prescribing disease modifying 
therapies as to the importance of their duty to report adverse events as they 
arise.  
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